2026-04-14T07:29:59Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1077502025-12-06T01:55:39Zcom_2072_1057col_2072_478809col_2072_478917

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain Darbà, Josep Ramírez, Gabriela García-Rivero, Juan L. Mayoralas, Sagrario Pascual, José Francisco Vargas, Diego Bijedic, Adi Administració de medicaments Malalties pulmonars obstructives cròniques Tractament tèrmic Economia de la salut Administration of drugs Chronic obstructive pulmonary diseases Heat treatment Medical economics The objective of this study was to estimate the economic impact of the introduction of DuoResp® Spiromax®, budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ... 2017-03-02T15:15:56Z 2017-03-02T15:15:56Z 2017-02 2017-03-02T15:15:56Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 1178-6981 https://hdl.handle.net/2445/107750 668396 28228660 eng Reproducció del document publicat a: https://doi.org/10.2147/CEOR.S125301 Clinicoeconomics and Outcomes Research, 2017, vol. 9, num. February, p. 127-137 https://doi.org/10.2147/CEOR.S125301 cc-by-nc (c) Darbà, Josep et al., 2017 http://creativecommons.org/licenses/by-nc/3.0/es info:eu-repo/semantics/openAccess 11 p. application/pdf Dove Medical Press Articles publicats en revistes (Economia)